LOGIN  |  REGISTER
Assertio
Astria Therapeutics

Syra Health Launches SyraBot, a digital health product

November 13, 2023 | Last Trade: US$0.39 0.02 5.38
  • SyraBot is Syra Health's third product launch in four weeks

CARMEL, Ind., Nov. 13, 2023 /PRNewswire/ -- Syra Health Corp. (NASDAQ: SYRA) ("Syra Health" or the "Company"), a healthcare company addressing some of healthcare's most significant challenges by providing innovative services and technology solutions, today announced the launch of SyraBot, a product available through the Company's Digital Health business unit.

SyraBot is Syra Health's human-centric AI-backed chatbot that delivers conversational and immediate responses to inquiries made through a healthcare organization's website, providing real-time access to information users need, twenty-four hours a day, seven days a week.

"SyraBot never sleeps, "said Dr. Deepika Vuppalanchi, CEO, Syra Health. "For that reason, it's a welcome addition to any healthcare organization's team."

Created in response to the increasing demands placed on administrative healthcare professionals, SyraBot emerges as a cost-effective solution by streamlining administrative tasks and reducing heavy workloads. SyraBot reduces the number of calls and time it takes to respond to duplicate inquiries, all while increasing user satisfaction.

SyraBot is inclusive, available in up to 200 languages and dialects, and accessible at a fifth-grade reading level or lower.

"SyraBot is a testament to our commitment to revolutionizing healthcare," said Sandeep Allam, Executive Chairman and President, Syra Health. "By combining accessibility, multilingual support, and a conversational interface, we believe SyraBot will play a pivotal role in shaping the future of digital health."

Syra Health has developed and customized SyraBot to serve three different segments within the healthcare space: payers, providers, and state governments.

The launch of SyraBot marks Syra Health's third product launch in just four weeks, underscoring the Company's commitment to addressing some of healthcare's largest challenges such as digital health. SyraBot intends to transform how users interact with digital health, making the experience personal, conversation and accessible.

ABOUT SYRA HEALTH CORP.

Syra Health is a healthcare company addressing some of healthcare's most significant challenges by providing innovative services and technology solutions. Syra Health specializes in behavioral and mental health, digital health, and population health. Syra Health's solutions are centered on prevention, improved access, and affordable care.

For more information, please visit www.syrahealth.com.

SAFE HARBOR STATEMENT

Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." These statements include, but are not limited to, statements relating to the expected use of proceeds, the Company's operations and business strategy and the Company's expected financial results. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements contained in this press release are based on management's current expectations and are subject to substantial risks, uncertainty and changes in circumstances. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors discussed in the "Risk Factors" section of the prospectus filed with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise.

For more information, please contact:

For Media Inquiries:
Syra Health
Communications and Marketing Director
Christine Drury
463-345-5180
This email address is being protected from spambots. You need JavaScript enabled to view it. 

For Investor Inquiries:
Ben Shamsian
Vice President
Lytham Partners, LLC
646-829-9701
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Terns Pharmaceuticals

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB